134 related articles for article (PubMed ID: 33645339)
1. Impact of
Helwa R; Gansmo LB; Bjørnslett M; Halle MK; Werner HMJ; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Biomarkers; 2021 Jun; 26(4):302-308. PubMed ID: 33645339
[TBL] [Abstract][Full Text] [Related]
2. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
[TBL] [Abstract][Full Text] [Related]
3. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
[TBL] [Abstract][Full Text] [Related]
4. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Bjørnslett M; Knappskog S; Lønning PE; Dørum A
BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
Helwa R; Gansmo LB; Romundstad P; Hveem K; Vatten L; Ryan BM; Harris CC; Lønning PE; Knappskog S
Sci Rep; 2016 Sep; 6():33153. PubMed ID: 27624283
[TBL] [Abstract][Full Text] [Related]
6. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
7. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
8. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
9. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
[TBL] [Abstract][Full Text] [Related]
10. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
11. MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
Knappskog S; Gansmo LB; Romundstad P; Bjørnslett M; Trovik J; Sommerfelt-Pettersen J; Løkkevik E; ; Tollenaar RA; Seynaeve C; Devilee P; Salvesen HB; Dørum A; Hveem K; Vatten L; Lønning PE
PLoS One; 2012; 7(4):e36263. PubMed ID: 22558411
[TBL] [Abstract][Full Text] [Related]
12. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
[TBL] [Abstract][Full Text] [Related]
13. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Dørum A; Birkeland E; Hveem K; Romundstad P; Vatten L; Lønning PE; Knappskog S
Tumour Biol; 2016 Aug; 37(8):10697-702. PubMed ID: 26867771
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399
[TBL] [Abstract][Full Text] [Related]
16. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
17. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
18. The association between murine double minute 2 (MDM2) rs2279744 and endometrial cancer risk in a Chinese Han population.
Wu JP; Luo X
Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):128-130. PubMed ID: 29096752
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]